Anti-IgE therapy (omalizumab) in IgE-ACPA positive RA.

Trial Profile

Anti-IgE therapy (omalizumab) in IgE-ACPA positive RA.

Phase of Trial: Phase II

Latest Information Update: 28 Apr 2014

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms TIGER
  • Most Recent Events

    • 23 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top